Active substanceLevetiracetamLevetiracetam
Similar drugsTo uncover
  • Zenicetam®
    pills inwards 
  • Kepayra Vero®
    pills inwards 
    VEROPHARM SA     Russia
  • Keppra®
    concentrate d / infusion 
    YUSB Farma S.A.     Belgium
  • Keppra®
    solution inwards 
    YUSB Farma S.A.     Belgium
  • Keppra®
    pills inwards 
    YUSB Farma S.A.     Belgium
  • Convilept®
    pills inwards 
  • Levitinol®
    pills inwards 
    GEROPHARM, LLC     Russia
  • Levitinol®
    solution inwards 
    GEROPHARM, LLC     Russia
  • Levetiracetam
    pills inwards 
  • Levetiracetam
    pills inwards 
  • Levetiracetam Canon
    pills inwards 
  • Letyram®
    pills inwards 
  • Thirapol
    pills inwards 
  • Thirapol
    solution inwards 
  • Elsertor
    pills inwards 
    Lupine Co., Ltd.     India
  • Epikepran
    pills inwards 
    NANOLEC, LTD.     Russia
  • Epitera
    pills inwards 
  • Epiterra Long
    pills inwards 
  • Epitropyl
    pills inwards 
  • Dosage form: & nbspRAstvor for oral administration.
    Composition:

    1 ml of the solution contains:

    Active substance: levetiracetam - 100.00 mg.

    Excipients: acesulfame potassium (E950) - 4.50 mg, ammonium glycyrrhizinate - 1.50 mg, citric acid monohydrate 0.06 mg, glycerol (E422) 200.00 mg, maltitol liquid (E965) 300.00 mg, methyl parahydroxybenzoate (E218) -2.70 mg, propyl parahydroxybenzoate (E216) 0.30 mg, sodium citrate dihydrate 1.05 mg, grape flavor 0.30 mg, purified water up to 1 ml.

    Description:

    A clear, colorless solution.

    Pharmacotherapeutic group:antiepileptic agent
    ATX: & nbsp

    N.03.A.X   Other antiepileptic drugs

    N.03.A.X.14   Levetiracetam

    Pharmacodynamics:

    Levetiracetam is a derivative of pyrrolidone (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine-acetamide) differing in chemical structure from known antiepileptic drugs.

    The mechanism of action of levetiracetam is not fully understood, but it differs from the mechanism of action of known antiepileptic drugs.

    Experiments in vitro and in vivo showed that levetiracetam does not affect the basic characteristics of cells and normal transmission.

    Research in vitro showed that levetiracetam affects the intra-neuronal concentration of calcium ions (Ca2+), partially inhibiting the current Sa2+ through the channels Ntype and reducing the release of Ca2+ from intra-neural depots. Besides, levetiracetam partially restores currents through GABA and glycine-dependent channels, reduced by zinc and P-carbolines.

    One of the proposed mechanisms is based on proven binding to the glycoprotein of synaptic vesicles SV2A, contained in the gray matter of the brain and spinal cord. It is believed that the anticonvulsant effect is realized in this way, which is expressed in counteracting the hypersynchronization of neuronal activity. Levetiracetam prevents the development of seizures in various experimental models of partial and primary generalized seizures without a proconvulsive effect. The main metabolite of levetiracetam is inactive.

    The drug's activity with respect to both focal and generalized epileptic seizures (epileptiform manifestations / photoparoxysmal reaction) confirms its wide spectrum of pharmacological action.

    Pharmacokinetics:

    Levetiracetam has a high solubility and permeability.

    Suction

    After oral administration levetiracetam quickly and almost completely absorbed from the gastrointestinal tract. Absorption is linear in nature, so the concentration of levetiracetam in the blood plasma is predictable, based on the accepted dose of the drug, expressed in mg / kg body weight. The degree of absorption does not depend on the dose and time of food intake. Bioavailability is about 100%. Maximum concentration in blood plasma (FROMmax), equal to 31 μg / ml, is achieved in 1.3 hours after a single dose of levetiracetam in a dose of 1000 mg, after repeated administration (2 times a day) - 43 μg / ml.

    The maximum concentration in children aged 4 to 12 years is reached after 0.5-1.0 hours after ingestion of levetiracetam in a dose of 20-60 mg / kg / day. The equilibrium state is achieved after 2 days with a two-time intake of the drug. The pharmacokinetics of levetiracetam in children in the dose range from 20 to 60 mg / kg / day is linear.

    Distribution

    The binding of levetiracetam and its main metabolite to plasma proteins is less than 10%. Volume of distribution (Vd) is about 0.5-0.7 l / kg.

    Metabolism

    Formation of a primary pharmacologically inactive metabolite (ucb L057) occurs without the involvement of liver cytochrome P450. Levetiracetam does not affect the enzymatic activity of hepatocytes. In conditions in vitro levetiracetam and its main metabolite did not inhibit the main cytochrome P450 isoenzymes (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), as well as the activity of glucuronyl transferase (UGT1A1 and UGT1A6) and epoxy hydroxylase.

    Levetiracetam also did not affect the glucuronation of valproic acid in vitro.

    Excretion

    The half-life (T1/2) from the blood plasma of an adult is 7 ± 1 h and does not depend on the mode of administration and dosing regimen. The average overall clearance is 0.96 ml / min / kg. 95% of the administered dose of the drug is excreted by the kidneys. The renal clearance of levetiracetam and its main metabolite is 0.6 and 4.2 ml / min / kg, respectively.

    Have elderly patients T1/2 increases by 40% and is 10-11 hours, which is associated with a decrease in excretory function of the kidney in this category of patients.

    Have patients with impaired renal function the clearance of levetiracetam and its primary metabolite correlates with creatinine clearance. Therefore, patients with renal failure are recommended to select a dose depending on the creatinine clearance.In the terminal stage of renal failure in adult patients, T1/2 is 25 h in the period between dialysis sessions and 3.1 h during dialysis. During a 4-hour dialysis session, up to 51% of levetiracetam is removed.

    Have patients with impaired liver function light and moderate degrees of gravity there are no significant changes in the clearance of levetiracetam. In most patients with severe impairment of liver function with concomitant renal failure, the clearance of levetiracetam declines by more than 50%.

    Children from 4 to 12 years old

    T1/2 in children aged 4-12 years after a single oral administration of the drug at a dose of 20 mg / kg of body weight is 6 hours. The total clearance of levetiracetam in children 4-12 years is approximately 30% higher than in adults and is directly dependent on the weight body. After repeated oral administration at a dose of 20-60 mg / kg of body weight to children 4-12 years of age, the maximum plasma concentration is reached after 0.5-1.0 h and increases linearly and proportionally to the dose. The average overall clearance is 1.1 ml / min / kg.

    Children from 1 month to 4 years

    T1/2 in children aged 1 month to 4 years after a single oral administration of 20 mg / kg body weight of the oral solution at a concentration of 100 mg / ml is 5.3 hours.The maximum plasma concentration is reached approximately in 1 hour after reception of a preparation. The average total clearance is 1.5 ml / min / kg.

    Indications:

    As a monotherapy in the treatment of:

    • partial seizures with secondary generalization or without it in adults and adolescents over 16 years with newly diagnosed epilepsy.

    As part of complex therapy in the treatment of:

    • partial seizures with secondary generalization or without it in adults and children older than 1 month with epilepsy;
    • myoclonic seizures in adults and adolescents over 12 years with juvenile myoclonic epilepsy;
    • primary-generalized convulsive tonic-clonic seizures in adults and adolescents over 12 years with idiopathic generalized epilepsy.

    Contraindications:

    - Hypersensitivity to levetiracetam or other pyrrolidone derivatives, as well as to any components of the drug; impaired tolerance to fructose;

    - Children under 1 month of age (safety and efficacy not established).

    Carefully:

    Patients of advanced age (over 65 years); liver disease in the stage of decompensation; renal insufficiency.

    Pregnancy and lactation:

    In post-marketing data obtained from several prospective pregnancy registries, more than 1,000 cases of monotherapy with levetiracetam in the first trimester of pregnancy have been recorded.

    In general, these data do not indicate a significant increase in the risk of serious congenital malformations, although teratogenic risk can not be completely ruled out. Therapy with several antiepileptic drugs is associated with a higher risk of congenital malformations than monotherapy, which is why monotherapy in pregnant women is more appropriate. Adequate and strictly controlled studies on the safety of levetiracetam in pregnant women have not been conducted. Studies in animals have revealed reproductive toxicity. Women with a preserved reproductive function during treatment with levetiracetam should take contraceptive measures. The drug should be administered during pregnancy only in case of emergency. Physiological changes in the body of a woman during pregnancy can affect the concentration in plasma of levetiracetam as well as other antiepileptic drugs.During pregnancy, there was a decrease in the concentration of levetiracetam in plasma. This decrease is more pronounced in the third trimester (up to 60% of the baseline concentration observed before pregnancy). Treatment with levetiracetam pregnant women should be carried out under special supervision. Interruptions in antiepileptic therapy may lead to a worsening of the course of the disease, which can harm the health of both the mother and the fetus.

    Levetiracetam is excreted in breast milk, so breastfeeding during treatment with the drug is not recommended. However, if treatment with levetiracetam is necessary during breastfeeding, the risk / benefit ratio should be carefully weighed against the importance of breastfeeding.

    Dosing and Administration:

    Inside, regardless of food intake.

    The daily dose of the drug is divided into two doses in the same dose.

    Monotherapy

    Adults and teens over 16 years of age

    Treatment should begin with a daily dose of 500 mg divided into 2 divided doses (250 mg twice a day). After 2 weeks, the dose may be increased to the initial therapeutic dose of 1000 mg (500 mg twice a day). The maximum daily dose is 3000 mg (1500 mg twice a day).

    As part of complex therapy

    Adults from 18 years and adolescents (12 to 17 years) with a body weight of more than 50 kg

    Treatment should begin with a daily dose of 1000 mg divided into 2 divided doses (500 mg each 2 times a day). Depending on the clinical response and the tolerability of the drug, the daily dose can be increased to a maximum of 3000 mg (1500 mg twice a day). A dose change of 500 mg 2 times a day can be carried out every 2-4 weeks.

    Use in special patient groups

    Patients with renal insufficiency

    Because the levetiracetam is excreted from the body by the kidneys, when the drug is administered patients with renal insufficiency and elderly patients (65 years and older) The dose should be adjusted depending on the amount of creatinine clearance (CC).

    Creatinine clearance (CC) for men can be calculated based on the serum creatinine concentration, according to the following formula:

    CK (ml / min) = [140 - age (years)] x body weight (kg)/ 72 х КTOserum (mg / dL)

    Creatinine clearance for women can be calculated by multiplying the obtained value by a factor of 0.85.

    Then the QC is adjusted taking into account the body surface area (PIT) according to the following formula:

    KK (ml / min / 1.73 m2) = KK (ml / min) / PPT of the facility (m2) x 1.73

    Renal insufficiency

    QC (ml / min / 1.73 m2)

    Dosing regimen

    Norm

    >80

    from 500 to 1500 mg twice a day

    Lightweight

    50-79

    from 500 to 1000 mg twice a day

    Moderate

    30-49

    from 250 to 750 mg twice a day

    Heavy

    <30

    from 250 to 500 mg twice a day

    Terminal stage (patients on dialysis *)

    from 500 to 1000 mg 1 once a day **

    * The first day of treatment is recommended to take a saturating dose of 750 mg;

    ** After dialysis, an additional 250-500 mg dose is recommended.

    Children with kidney failure correction of the dose of levetiracetam should be made taking into account the degree of renal failure.

    Creatinine clearance (ml / min / 1.73 m2) can be assessed based on serum creatinine (mg / dL) for adolescents, children and newborns using the following formula (Schwartz formula):

    KK (ml / min / 1.73 m2) = Height (cm) x ks/ QCserum (mg / dL)

    ks = 0.45 for children under 1 year;

    ks = 0.55 for children under 13 and females;

    ks = 0.7 for adolescent males.

    Dosing for newborns, children and adolescents weighing less than 50 kg with impaired renal function

    Renal failure

    QC

    (ml / min / 1.73 m2)

    Dosing regimen

    age from 1 to 6 months

    age from 6 to 23 months, children

    Norm

    >80

    7-21 mg / kg (0.07-0.21 ml / kg) twice daily

    10-30 mg / kg (0.10-0.30 ml / kg) twice daily

    Lightweight

    50-79

    7-14 mg / kg (0.07-0.14 ml / kg) twice daily

    10-20 mg / kg (0.10-0.20 ml / kg) twice daily

    Moderate

    30-49

    3,5-10,5 mg / kg (0,035-0,105 ml / kg) 2 times a day

    5-15 mg / kg (0.05-0.15 ml / kg) twice daily

    Heavy

    <30

    3.5-7 mg / kg (0.035-0.07 ml / kg) twice daily

    5-10 mg / kg (0.05-0.10 ml / kg) twice daily

    Terminal stage (patients on dialysis *)

    -

    7-14 mg / kg (0.07-0.14 ml / kg)

    1 time per day (1) (3)

    10-20 mg / kg (0.10-0.20 ml / kg)

    1 time per day (2) (4)

    (1) - 10.5 mg / kg (0.105 ml / kg) the recommended loading dose on the first day of treatment;

    (2) - 15 mg / kg (0.15 ml / kg) the recommended loading dose on the first day of treatment;

    (3) - recommended maintenance dose after dialysis 3.5-7 mg / kg (0.035-0.07 ml / kg);

    (4) is the recommended maintenance dose after dialysis of 5-10 mg / kg (0.05-0.10 ml / kg).

    Patients with impaired hepatic function

    Patients with a malfunction of the liver of mild to moderate severity are not required to adjust the dose.

    In patients with severe decompensated impairment of liver function and renal insufficiency the level of decrease in the clearance of creatinine may not fully reflect the severity of renal failure. In such cases, when creatinine clearance <60 ml / min / 1.73, a daily dose reduction of 50% is recommended.

    Use in children

    Children aged 6 months to 23 months, children aged 2 to 11 years and adolescents from 12 to 17 years of age with a body weight of less than 50 kg

    Treatment should begin with a dose of 20 mg / kg body weight divided into 2 divided doses (10 mg / kg body weight 2 times a day). Depending on the clinical response and the tolerability of the drug, the daily dose can be increased to 30 mg / kg 2 times a day. A dose change of 20 mg / kg (10 mg / kg body weight 2 times a day) of body weight can be done every 2 weeks. The minimum effective dose should be used.

    Recommended dosages for children (from 6 months) and adolescents:

    Body mass

    Initial dose

    The maximum dose

    (10 mg / kg 2 times a day)

    (30 mg / kg 2 times a day)

    6 kg *

    60 mg (0.6 ml) twice daily

    180 mg (1.8 ml) twice daily

    10 kg *

    100 mg (1 ml) twice daily

    300 mg (3 ml) twice daily

    15 kg *

    150 mg (1.5 ml) twice daily

    450 mg (4.5 ml) twice daily

    20 kg *

    200 mg (2 ml) twice daily

    600 mg (6 ml) twice daily

    25 kg *

    250 mg twice daily

    750 mg twice a day

    from 50 kg **

    500 mg twice a day

    1500 mg twice a day

    * For children with a body weight of 25 kg or less, it is preferable to begin treatment with the administration of a solution for ingestion of Tiraspol 100 mg / ml.

    ** Dosage for children and adolescents with a body weight of more than 50 kg is the same as for adults.

    Children aged 1 month to 6 months

    The initial treatment dose is 7 mg / kg twice a day.

    Depending on the clinical efficacy and tolerability, the dose can be increased to 21 mg / kg twice a day.The dose change should not exceed plus or minus 7 mg / kg twice a day every two weeks. The minimum effective dose should be given.

    Dosage recommendations for children under 6 months of age

    Body mass

    The initial dose (7 mg / kg twice daily)

    The maximum dose (21 mg / kg twice a day)

    4 kg

    28 mg (0.3 ml) twice daily

    84 mg (0.85 ml) twice daily

    5 kg

    35 mg (0.35 ml) twice daily

    105 mg (1.05 ml) twice daily

    7 kg

    49 mg (0.5 ml) twice daily

    147 mg (1.5 ml) twice daily

    Dosage of the solution is carried out with the help of the measuring syringes included in the delivery package of the preparation.

    There are syringes of nominal capacity:

    - 12 ml (corresponding to 1200 mg levetiracetam) and with a 0.25 ml fission rate (corresponding to 25 mg) for children 4 years and older, adolescents and adults;

    - 3 ml (corresponding to 300 mg) with a fission rate of 0.1 ml (corresponding to 10 mg) for children aged 6 months to 4 years;

    - 1 ml (corresponding to 100 mg) and the cost of dividing 0.05 ml (corresponding to 5 mg) for children aged 1 month to 6 months.

    A metered dose of the drug is diluted in a glass of drinking water or a baby bottle.

    Instructions for dosing a solution using a measuring syringe:

    - Open the bottle: to do this, click on the cap and rotate it counter-clockwise (Fig.1).

    - Separate the adapter from the syringe (Figure 2). Insert the syringe adapter into the neck of the vial, make sure it is well fixed, then take the syringe and place it in the adapter.

    - Turn the bottle upside down (Fig. 3).

    - Fill the syringe with a small amount of solution, pulling the piston down, then push the piston upward to remove air bubbles (Fig. 4a, 4b).

    - Fill the syringe with the solution, pulling the piston to the division corresponding to the number of milliliters (ml) of the solution prescribed by the doctor dose (Fig. 4c).

    - Turn the bottle upside down and pull the syringe out of the adapterera.

    - Enter the contents of the syringe into a glass of drinking water or a baby bottle, pressing the piston against the stop (Fig. 5).

    - It is necessary to drink completely all the contents of the glass (or baby bottle).

    - Rinse the syringe with drinking water (Figure 6).

    - Close the bottle with a screw cap.

    Side effects:

    The most frequently reported adverse reactions are nasopharyngitis, drowsiness, headache, weakness, dizziness. The safety profile of levetiracetam is generally similar for different age groups of adults and children.

    The incidence of side effects is classified according to the recommendations of the World Health Organization: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000,<1/100), rarely (> 1/10 000, <1/1000), very rarely (<1/10 000, including individual messages); frequency is unknown - insufficient data to estimate the frequency of development.

    Infectious and parasitic diseases: very often - nasopharyngitis; rarely - infection.

    Violations of the blood and lymphatic system: infrequently - thrombocytopenia, leukopenia; rarely - pancytopenia (in some cases, bone marrow depression was recorded), neutropenia.

    Immune system disorders: rarely - drug allergy with eosinophilia and systemic manifestations (DRESS-syndrome).

    Disorders from the metabolism and nutrition: often - anorexia; infrequently - weight loss, weight gain; rarely - hyponatremia.

    Disorders of the psyche: often - depression, hostility, aggression, anxiety, insomnia, nervousness, irritability; infrequently - suicide attempts, suicidal thoughts, psychotic disorders, behavioral disorders, hallucinations, anger, confusion, panic attacks, emotional lability, mood swings, agitation; rarely - suicide, personality disorder, violation of thinking.

    Disturbances from the nervous system: very often - drowsiness, headache; often - convulsions, imbalance, dizziness, lethargy, tremor; infrequently - amnesia, memory impairment, coordination disorder / ataxia, paresthesia, decreased concentration of attention; rarely - choreoathetosis, dyskinesia, hyperkinesia.

    Disturbances on the part of the organ of sight: infrequently - diplopia, blurred vision.

    Hearing disorders and labyrinthine disorders: often - vertigo.

    Disturbances from the respiratory system, chest and mediastinal organs: often - a cough.

    Disorders from the gastrointestinal tract: often - abdominal pain, diarrhea, indigestion, vomiting, nausea; rarely - pancreatitis.

    Disturbances from the side of baked and bile ducts: infrequent - deviation of laboratory parameters of liver function from the norm; rarely - hepatic insufficiency, hepatitis.

    Disturbance of the skin and subcutaneous tissues: often - skin rash; infrequently - alopecia, eczema, itching; rarely - toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme.

    Disturbances from musculoskeletal and connective tissue: infrequently - muscle weakness, myalgia.

    General disorders and disorders at the site of administration: very often - general weakness / fatigue.

    Injuries, intoxication and complications of manipulation: infrequent - accidental damage.

    With the simultaneous administration of levetiracetam and topiramate, the likelihood of developing anorexia increases.

    In a number of cases, restoration of the hair was observed after the removal of levetiracetam.

    The safety profile of levetiracetam generally does not differ depending on age (in adults and children), and also does not depend on approved indications for use (various variants of epilepsy). With the exception of behavioral and psychiatric adverse reactions that occur more frequently in children than in adults, the safety profile of children is comparable to the safety profile of levetiracetam in adults.

    Children and adolescents aged 4 to 16 years The following undesirable reactions were more often recorded: vomiting (very often, 11.2%), excitation (often, 3.4%), moodiness (often 2.1%), emotional lability (often, 1.7%), aggressiveness (often, 8.2%), behavioral disorders (often, 5.6%) and lethargy (often, 3.9%).

    Children aged from 1 month to 4 years The following undesirable reactions were more often recorded: irritability (very often 11.7%) and impaired coordination (often, 3.3%).

    Overdose:

    Symptoms: drowsiness, agitation, aggressiveness, oppression of consciousness, respiratory depression, coma.

    Treatment: in the acute period - artificial vomiting and gastric lavage followed by the appointment of activated charcoal. There is no specific antidote for levetiracetam. If necessary, symptomatic treatment in a hospital using hemodialysis (dialysis efficiency for levetiracetam is 60%, for its primary metabolite - 74%).

    Interaction:

    Antiepileptic agents

    Levetiracetam does not affect the plasma concentration of antiepileptic drugs (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidon), which in turn do not affect the concentration of levetiracetam. Similar to adults, in children at doses up to 60 mg / kg / day levetiracetam does not interact with other drugs.

    A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4-17 years) confirms that levetiracetam as an auxiliary therapy does not affect the equilibrium serum concentrations of simultaneously used carbamazepine and valproic acid. However, there is evidence that the clearance of levetiracetam is 20% higher in children taking anticonvulsants - inducers of microsomal liver enzymes compared to children who do not take them. Correction of the dose is not required.

    Probenecid

    Probenecid is a blocker of tubular secretion in the kidneys. It is shown that when probenecid is administered at a dose of 500 mg 4 times a day, it inhibits renal clearance of the main metabolite, but not levetiracetam. Nevertheless, the concentration of the main metabolite remains low. It is assumed that other drugs excreted through active tubular secretion, can reduce the renal clearance of the main metabolite. The effect of levetiracetam with simultaneous administration with probenecid has not been studied, nor is it known when taken with other drugs excreted by active tubular secretion, including non-steroidal anti-inflammatory drugs, sulfonamides and methotrexate.

    Oral contraceptives and other pharmacokinetic interactions

    Levetiracetam in a daily dose of 1000 mg does not affect the pharmacokinetics of oral contraceptives (ethinyl estradiol and levonorgestrel); The hormonal status (the content of luteinizing hormone and progesterone) does not change.

    Levetiracetam in a daily dose of 2000 mg does not change the pharmacokinetics of digoxin and warfarin; prothrombin time does not change.

    The simultaneous use of digoxin, oral contraceptives and warfarin does not affect the pharmacokinetics of levetiracetam.

    Antacids

    There is no data on the effect of antacids on the absorption of levetiracetam.

    Laxatives

    There are some reports of a decrease in the efficacy of levetiracetam when administered concurrently with a laxative macrogol. Macrogol Do not use 1 hour before and 1 hour after taking levetiracetam.

    Food and alcohol

    Completeness of absorption of levetiracetam does not change under the influence of food, while the rate of absorption is somewhat reduced.

    There are no data on the interaction of levetiracetam with alcohol.

    Special instructions:

    Abolition of therapy

    If it is necessary to stop taking the drug, the abolition of treatment in adults and adolescents with a body weight of more than 50 kg is recommended to be carried out gradually, reducing the single dose by 500 mg every 2-4 weeks. In children, the dose reduction should not exceed 10 mg / kg of body weight 2 times a day every 2 weeks, in children less than 6 months, the dose reduction should not exceed 7 mg / kg of body weight 2 times a day every 2 weeks.

    During the transfer of patients to the administration of levetiracetam, the antiepileptic drugs previously used should be gradually phased out. The available information on the use of the drug in children does not indicate any of its negative effects on development and puberty. However, the long-term consequences of treatment on the ability of children to learn, their intellectual development, growth, endocrine gland functions, sexual development and fertility remain unknown.

    Renal insufficiency

    Patients with kidney disease and decompensated liver disease are recommended to study the function of the kidneys before treatment. If the kidney function is impaired, a dose adjustment may be required.

    Suicide

    In patients taking anticonvulsants (including levetiracetam) there were cases of suicide, suicide attempts, suicidal thoughts and behavior. A meta-analysis of randomized placebo-controlled trials of anticonvulsant drugs showed a slight excess of the risk of suicidal thoughts and behavior. The mechanism of its implementation is not known. It is necessary to monitor patients with symptoms of depression or suicidal thoughts and behavior and prescribe appropriate therapy. Patients (as well as carers) should be informed of the need to seek medical help if they develop symptoms of depression and / or suicidal thoughts and behavior.

    Intolerance to fructose

    Tiraspol solution for oral administration contains maltitol, therefore, in patients with impaired tolerance to fructose, taking the drug in this dosage form is contraindicated.

    Allergic reactions

    The oral solution also contains methyl parahydroxybenzoate and propyl parahydroxybenzoate, which can cause allergic reactions (possibly delayed action).

    Effect on the ability to drive transp. cf.and fur:

    The effect of the drug on the ability to drive vehicles and control mechanisms is not specifically studied. However, due to different individual sensitivity to the drug, from the side of the central nervous system during the treatment period (some patients may experience drowsiness), it is necessary to refrain from driving vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

    Form release / dosage:

    Solution for oral administration, 100 mg / ml.

    Packaging:

    150 ml or 300 ml in a bottle of brown glass, sealed with a polyethylene screw cap with childproof protection and a first-opening control ring.

    One vial with instructions for use and a measuring syringe (1 ml or 3 ml for a 150 ml bottle or 12 ml for a 300 ml bottle) with a adapter adapter is placed in a cardboard box.

    Storage conditions:

    Store in the original packaging at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    The vial should be used within 7 months.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002806
    Date of registration:12.01.2015
    Expiration Date:12.01.2020
    The owner of the registration certificate:Pharmaceutical factory "POLFARMA" JSCPharmaceutical factory "POLFARMA" JSC Poland
    Manufacturer: & nbsp
    Representation: & nbspAKRIKHIN OJSC AKRIKHIN OJSC Russia
    Information update date: & nbsp20.10.2016
    Illustrated instructions
      Instructions
      Up